

# Reiner Wiest

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11291970/publications.pdf>

Version: 2024-02-01

86  
papers

12,383  
citations

101543

36  
h-index

53230

85  
g-index

88  
all docs

88  
docs citations

88  
times ranked

16877  
citing authors

#	ARTICLE	IF	CITATIONS
1	Changes of Intestinal Functions in Liver Cirrhosis. <i>Inflammatory Intestinal Diseases</i> , 2016, 1, 24-40.	1.9	4,709
2	Bacterial infections in cirrhosis: A position statement based on the EASL Special Conference 2013. <i>Journal of Hepatology</i> , 2014, 60, 1310-1324.	3.7	685
3	Pathological bacterial translocation in liver cirrhosis. <i>Journal of Hepatology</i> , 2014, 60, 197-209.	3.7	651
4	Bacterial translocation (BT) in cirrhosis. <i>Hepatology</i> , 2005, 41, 422-433.	7.3	611
5	The paradox of nitric oxide in cirrhosis and portal hypertension: Too much, not enough. <i>Hepatology</i> , 2002, 35, 478-491.	7.3	408
6	Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development. <i>Journal of Hepatology</i> , 2019, 71, 1216-1228.	3.7	388
7	Bacterial and fungal infections in acute-on-chronic liver failure: prevalence, characteristics and impact on prognosis. <i>Gut</i> , 2018, 67, 1870-1880.	12.1	375
8	Targeting the gut-liver axis in liver disease. <i>Journal of Hepatology</i> , 2017, 67, 1084-1103.	3.7	311
9	Microbial network disturbances in relapsing refractory Crohn's disease. <i>Nature Medicine</i> , 2019, 25, 323-336.	30.7	277
10	DSS induced colitis increases portal LPS levels and enhances hepatic inflammation and fibrogenesis in experimental NASH. <i>Journal of Hepatology</i> , 2011, 55, 1391-1399.	3.7	250
11	Systemic chemerin is related to inflammation rather than obesity in type 2 diabetes. <i>Clinical Endocrinology</i> , 2010, 72, 342-348.	2.4	240
12	Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in Europe. <i>Journal of Hepatology</i> , 2019, 70, 398-411.	3.7	225
13	Prevention of Rebleeding From Esophageal Varices in Patients With Cirrhosis Receiving Small-Diameter Stents Versus Hemodynamically Controlled Medical Therapy. <i>Gastroenterology</i> , 2015, 149, 660-668.e1.	1.3	196
14	Gut microflora in the pathogenesis of the complications of cirrhosis. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2004, 18, 353-372.	2.4	181
15	The window hypothesis: haemodynamic and non-haemodynamic effects of $\beta^2$ -blockers improve survival of patients with cirrhosis during a window in the disease: Figure 1. <i>Gut</i> , 2012, 61, 967-969.	12.1	180
16	Bacterial translocation in the gut. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2003, 17, 397-425.	2.4	175
17	Nitric Oxide and Portal Hypertension: Its Role in the Regulation of Intrahepatic and Splanchnic Vascular Resistance. <i>Seminars in Liver Disease</i> , 1999, 19, 411-426.	3.6	172
18	Intestinal bacterial translocation in rats with cirrhosis is related to compromised paneth cell antimicrobial host defense. <i>Hepatology</i> , 2012, 55, 1154-1163.	7.3	164

#	ARTICLE	IF	CITATIONS
19	FXR modulates the gut-vascular barrier by regulating the entry sites for bacterial translocation in experimental cirrhosis. <i>Journal of Hepatology</i> , 2019, 71, 1126-1140.	3.7	153
20	Cirrhosis-associated immune dysfunction. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 112-134.	17.8	139
21	Enhanced release of nitric oxide in response to changes in flow and shear stress in the superior mesenteric arteries of portal hypertensive rats. <i>Hepatology</i> , 1998, 28, 1467-1473.	7.3	126
22	Role of TLR9 in hepatic stellate cells and experimental liver fibrosis. <i>Biochemical and Biophysical Research Communications</i> , 2008, 376, 271-276.	2.1	125
23	Over-the-Scope Clips Are More Effective Than Standard Endoscopic Therapy for Patients With Recurrent Bleeding of Peptic Ulcers. <i>Gastroenterology</i> , 2018, 155, 674-686.e6.	1.3	122
24	Automated low flow pump system for the treatment of refractory ascites: A multi-center safety and efficacy study. <i>Journal of Hepatology</i> , 2013, 58, 922-927.	3.7	114
25	Octreotide potentiates PKC-dependent vasoconstrictors in portal-hypertensive and control rats. <i>Gastroenterology</i> , 2001, 120, 975-983.	1.3	90
26	NO overproduction by eNOS precedes hyperdynamic splanchnic circulation in portal hypertensive rats. <i>American Journal of Physiology - Renal Physiology</i> , 1999, 276, G1043-G1051.	3.4	76
27	Hsp90 regulation of endothelial nitric oxide synthase contributes to vascular control in portal hypertension. <i>American Journal of Physiology - Renal Physiology</i> , 1999, 277, G463-G468.	3.4	73
28	Non-selective beta-blockers may reduce risk of hepatocellular carcinoma: a meta-analysis of randomized trials. <i>Liver International</i> , 2015, 35, 2009-2016.	3.9	65
29	Genetic susceptibility to increased bacterial translocation influences the response to biological therapy in patients with Crohn's disease. <i>Gut</i> , 2014, 63, 272-280.	12.1	62
30	<i>NOD2</i> gene variants are a risk factor for culture-positive spontaneous bacterial peritonitis and monomicrobial bacterascites in cirrhosis. <i>Liver International</i> , 2012, 32, 223-230.	3.9	59
31	Bacterial translocation up-regulates GTP-cyclohydrolase I in mesenteric vasculature of cirrhotic rats. <i>Hepatology</i> , 2003, 38, 1508-1515.	7.3	53
32	Up-regulation of nNOS and associated increase in nitrenergic vasodilation in superior mesenteric arteries in pre-hepatic portal hypertension. <i>Journal of Hepatology</i> , 2005, 43, 258-265.	3.7	46
33	Antimicrobial peptide response to blood translocation of bacterial DNA in Crohn's disease is affected by NOD2/CARD15 genotype. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 1641-1650.	1.9	44
34	Splanchnic and Systemic Vasodilation. <i>Journal of Clinical Gastroenterology</i> , 2007, 41, S272-S287.	2.2	40
35	Dysbiotic microbiota interactions in Crohn's disease. <i>Gut Microbes</i> , 2021, 13, 1949096.	9.8	38
36	Systemic and hepatic vein galectin-3 are increased in patients with alcoholic liver cirrhosis and negatively correlate with liver function. <i>Cytokine</i> , 2011, 55, 435-440.	3.2	37

#	ARTICLE	IF	CITATIONS
37	Impaired hepatic removal of interleukin-6 in patients with liver cirrhosis. <i>Cytokine</i> , 2011, 53, 178-183.	3.2	35
38	Gut microbiome and intestinal barrier failure – The –Achilles heel– in hepatology?. <i>Journal of Hepatology</i> , 2012, 56, 1221-1223.	3.7	35
39	Gut Bacterial DNA Translocation is an Independent Risk Factor of Flare at Short Term in Patients With Crohn’s Disease. <i>American Journal of Gastroenterology</i> , 2016, 111, 529-540.	0.4	34
40	Amelioration of portal hypertension and the hyperdynamic circulatory syndrome in cirrhotic rats by neuropeptide Y via pronounced splanchnic vasoaction. <i>Gut</i> , 2011, 60, 1122-1132.	12.1	33
41	Uncoupling of sympathetic nervous system and hypothalamic–pituitary–adrenal axis in cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 1901-1908.	2.8	31
42	Bacterial translocation increases phagocytic activity of polymorphonuclear leucocytes in portal hypertension: priming independent of liver cirrhosis. <i>Liver International</i> , 2008, 28, 1149-1157.	3.9	28
43	Analysis of monocyte chemotactic protein-1 genepolymorphism in patients with spontaneous bacterialperitonitis. <i>World Journal of Gastroenterology</i> , 2009, 15, 5558.	3.3	25
44	Splanchnic concentrations and postprandial release of visceral adipokines. <i>Metabolism: Clinical and Experimental</i> , 2010, 59, 664-670.	3.4	25
45	Portal vein omentin is increased in patients with liver cirrhosis but is not associated with complications of portal hypertension. <i>European Journal of Clinical Investigation</i> , 2013, 43, 926-932.	3.4	22
46	Can non-selective beta-blockers prevent hepatocellular carcinoma in patients with cirrhosis?. <i>Medical Hypotheses</i> , 2013, 81, 871-874.	1.5	21
47	Reduced serum chemerin in patients with more severe liver cirrhosis. <i>Experimental and Molecular Pathology</i> , 2015, 98, 208-213.	2.1	21
48	Heme oxygenase-1 overexpression increases liver injury after bile duct ligation in rats. <i>World Journal of Gastroenterology</i> , 2007, 13, 3478.	3.3	21
49	Systemic saturated lysophosphatidylcholine is associated with hepatic function in patients with liver cirrhosis. <i>Prostaglandins and Other Lipid Mediators</i> , 2016, 124, 27-33.	1.9	20
50	Alterations in mechanical properties of mesenteric resistance arteries in experimental portal hypertension. <i>American Journal of Physiology - Renal Physiology</i> , 2009, 297, G849-G857.	3.4	19
51	Enhanced Y1-receptor-mediated vasoconstrictive action of neuropeptide Y (NPY) in superior mesenteric arteries in portal hypertension. <i>Journal of Hepatology</i> , 2006, 44, 512-519.	3.7	17
52	Soluble CD163 is not increased in visceral fat and steatotic liver and is even suppressed by free fatty acids in vitro. <i>Experimental and Molecular Pathology</i> , 2011, 91, 733-739.	2.1	17
53	Transjugular intrahepatic portosystemic shunt-placement increases arginine/asymmetric dimethylarginine ratio in cirrhotic patients. <i>World Journal of Gastroenterology</i> , 2008, 14, 7214.	3.3	17
54	Evaluation of treatment response after chemoembolisation (TACE) in hepatocellular carcinoma using real time image fusion of contrast-enhanced ultrasound (CEUS) and computed tomography (CT) - Preliminary results. <i>Clinical Hemorheology and Microcirculation</i> , 2014, 57, 191-201.	1.7	16

#	ARTICLE	IF	CITATIONS
55	Paneth cells promote angiogenesis and regulate portal hypertension in response to microbial signals. <i>Journal of Hepatology</i> , 2020, 73, 628-639.	3.7	16
56	Associations of systemic sphingolipids with measures of hepatic function in liver cirrhosis are related to cholesterol. <i>Prostaglandins and Other Lipid Mediators</i> , 2017, 131, 25-32.	1.9	14
57	Dietary glycine blunts liver injury after bile duct ligation in rats. <i>World Journal of Gastroenterology</i> , 2008, 14, 5996.	3.3	14
58	Isoproterenol Disrupts Intestinal Barriers Activating Gut-Liver-Axis: Effects on Intestinal Mucus and Vascular Barrier as Entry Sites. <i>Digestion</i> , 2020, 101, 717-729.	2.3	13
59	Evaluating key characteristics of ideal colorectal cancer screening modalities: the microsimulation approach. <i>Gastrointestinal Endoscopy</i> , 2021, 94, 379-390.e7.	1.0	12
60	Proprotein convertase subtilisin/kexin type 9 (PCSK9) levels are not associated with severity of liver disease and are inversely related to cholesterol in a cohort of thirty eight patients with liver cirrhosis. <i>Lipids in Health and Disease</i> , 2021, 20, 6.	3.0	11
61	Role of HSP-90 for increased nNOS-mediated vasodilation in mesenteric arteries in portal hypertension. <i>World Journal of Gastroenterology</i> , 2010, 16, 1837.	3.3	11
62	Neuropeptide Y restores non- $\alpha$ 1-antitrypsin receptor-mediated vasoconstrictive action in superior mesenteric arteries in portal hypertension. <i>Liver International</i> , 2015, 35, 2556-2563.	3.9	10
63	Pentraxin-3 is not related to disease severity in cirrhosis and hepatocellular carcinoma patients. <i>Clinical and Experimental Medicine</i> , 2020, 20, 289-297.	3.6	10
64	Connective tissue growth factor level is increased in patients with liver cirrhosis but is not associated with complications or extent of liver injury. <i>Regulatory Peptides</i> , 2012, 179, 10-14.	1.9	9
65	Circulating lipocalin 2 is neither related to liver steatosis in patients with non-alcoholic fatty liver disease nor to residual liver function in cirrhosis. <i>Cytokine</i> , 2016, 85, 45-50.	3.2	9
66	Bacterial Translocation. <i>Bioscience and Microflora</i> , 2005, 24, 61-90.	0.5	9
67	Tailored access to the hepatobiliary system in post-bariatric patients: a tertiary care bariatric center experience. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2020, 34, 5469-5476.	2.4	8
68	Rapid Decline of Serum Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) in Non-Cirrhotic Patients with Chronic Hepatitis C Infection Receiving Direct-Acting Antiviral Therapy. <i>Journal of Clinical Medicine</i> , 2021, 10, 1621.	2.4	8
69	Portal levels of latent transforming growth factor- $\beta$ 2 are related to liver function in patients with liver cirrhosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2011, 23, 218-223.	1.6	6
70	Alcoholic Cirrhosis Increases Risk for Autoimmune Diseases: A Nationwide Registry-Based Cohort Study. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 2017-2022.	4.4	6
71	Reply to: "Bacterial translocation in liver cirrhosis: Site and role in fibrogenesis". <i>Journal of Hepatology</i> , 2014, 61, 710-711.	3.7	5
72	Circulating fibroblast growth factor 21 in patients with liver cirrhosis. <i>Clinical and Experimental Medicine</i> , 2018, 18, 63-69.	3.6	5

#	ARTICLE	IF	CITATIONS
73	Actual Anti-TNF Trough Levels Relate to Serum IL-10 in Drug-Responding Patients With Crohn's Disease. Inflammatory Bowel Diseases, 2019, 25, 1357-1366.	1.9	5
74	Diagnostic Value of Systemic Cholesteryl Ester/Free Cholesterol Ratio in Hepatocellular Carcinoma. Anticancer Research, 2017, 37, 3527-3535.	1.1	5
75	Genotype-phenotype associations of polymorphisms within the gene locus of NOD-like receptor pyrin domain containing 3 in Swiss inflammatory bowel disease patients. BMC Gastroenterology, 2021, 21, 310.	2.0	5
76	Use of a cardiac occluder for closure of a complex gastric leak after bariatric surgery. Endoscopy, 2014, 46, E487-E488.	1.8	4
77	Serum Amyloid Beta42 Is Not Eliminated by the Cirrhotic Liver: A Pilot Study. Journal of Clinical Medicine, 2021, 10, 2669.	2.4	4
78	Soluble CD137 is a novel serum marker of liver cirrhosis in patients with hepatitis C and alcohol-associated disease etiology. European Journal of Immunology, 2022, 52, 633-645.	2.9	4
79	Increased plasma levels and more pronounced vasoconstrictive action of neuropeptide Y in the splanchnic circulation in portal hypertension. Gastroenterology, 2003, 124, A75-A76.	1.3	2
80	Successful Treatment of Small Intestinal Bleeding in a Crohn's Patient with Noncirrhotic Portal Hypertension by Transjugular Portosystemic Shunt Placement and Infliximab Treatment. Case Reports in Gastroenterology, 2017, 10, 589-595.	0.6	2
81	Determination of bile acids from human gallbladder by 1H-MRS Protocol optimization and estimation of reproducibility. NMR in Biomedicine, 2021, 34, e4432.	2.8	2
82	<scp>NOD</scp>2 gene variants and spontaneous bacterial peritonitis: authors' reply. Liver International, 2012, 32, 521-522.	3.9	1
83	The Gut Microbiome and Cirrhosis: Basic Aspects. , 2016, , 139-168.		1
84	Bacterial Translocation and Alterations of the Digestive System. , 2011, , 189-218.		1
85	Hepatocyte expressed chemerin-156 does not protect from experimental non-alcoholic steatohepatitis. Molecular and Cellular Biochemistry, 2022, , 1.	3.1	1
86	Editorial: The Role of Myeloid-Derived Cells in the Progression of Liver Disease. Frontiers in Immunology, 2019, 10, 2208.	4.8	0